Business
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025
MOUNTAIN VIEW, Calif., August 20, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 8-10, 2025.
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f7761fdf4d0920c22587b8bf83edac77"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7cFFiqeWHRjZIunhS65KpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f7761fdf4d0920c22587b8bf83edac77","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/f9ov_qXvyNsEG_FUpgRJxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/f7761fdf4d0920c22587b8bf83edac77","width":1024,"height":512}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., August 20, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 8-10, 2025.","length":530,"tagName":"p"},{"type":"text","content":"Mr. Bagai will be conducting a virtual presentation, which will be available for the duration of the conference, and afterwards on the Company's IR website at https://ir.renovorx.com/news-events/ir-calendar-events.","length":218,"tagName":"p"},{"type":"text","content":"Mr. Bagai will discuss RenovoRx’s ongoing commercialization efforts and the organic revenue growth reflecting the strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers.","length":253,"tagName":"p"},{"type":"text","content":"Mr. Bagai’s presentation will also highlight the latest developments in RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial, including the Data Monitoring Committee’s (DMC) recent recommendation to continue the trial following its review of the second pre-planned interim analysis which was triggered by the 52nd death. The TIGeR-PaC trial is evaluating RenovoRx’s novel drug-device combination oncology product candidate (intra-arterial gemcitabine deliv...